



(12) Translation of
European patent specification

(11) NO/EP 3191120 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 39/00 (2006.01)
C07K 16/24 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.08.19
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.04.10
(86)	European Application Nr.	15767597.6
(86)	European Filing Date	2015.09.08
(87)	The European Application's Publication Date	2017.07.19
(30)	Priority	2014.09.10, US, 201462048512 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	NOVARTIS AG, Lichtstrasse 35, 4056 Basel, Sveits
(72)	Inventor	MPOFU, Shephard, c/o Novartis Pharma AG Postfach, 4002 Basel, Sveits RICHARDS, Hanno, c/o Novartis Pharma AG Postfach, 4002 Basel, Sveits LIGOZIO, Gregory, c/o Novartis Pharmaceuticals Corporation One Health Plaza, East Hanover, NJ 07936, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54) Title **USE OF IL-17 ANTAGONISTS TO INHIBIT THE PROGRESSION OF STRUCTURAL DAMAGE IN PSORIATIC ARTHRITIS PATIENTS**

(56) References
Cited: WO-A1-2012/045848, WO-A1-2006/013107, WO-A1-2013/077907, WO-A1-2012/082573
Alice B Gottlieb ET AL: "AB0738 - Secukinumab Reduces HsCRP Levels in Subjects with Moderate-To-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis: A Sub-Analysis from the Phase 3 Erasme Study", Annals of the Rheumatic Diseases, 1 January 2014 (2014-01-01), pages 1-1, XP055227757, DOI: 10.1136/annrheumdis-2014-eular.1109 Retrieved from the Internet: URL:http://ard.bmj.com/content/73/Suppl_2/1047.2.abstract [retrieved on 2015-11-11]
Alice B. Gottlieb ET AL: "Secukinumab Shows Substantial Improvement In Both Psoriasis Symptoms and Physical Functioning In Moderate-To-Severe Plaque Psoriasis Patients With Psoriatic Arthritis: A Subanalysis Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study", American College of Rheumatology Meeting Abstracts, 1 January 2013 (2013-01-01), pages 1-4, XP055227813, Retrieved from the Internet: URL:<http://acrabstracts.org/abstract/secukinumab-shows-substantial-improvement-in-both-psoriasis-symptoms-and-physical-functioning-in-moderate-to-severe-plaque-psoriasis-patients-with-psoriatic-arthritis-a-subanalysis-of-a-phase-3-multicenter-double-blind-placebo-controlled-study> [retrieved on 2015-11-11]
SARAH L. GAFFEN ET AL: "The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing", THE JOURNAL OF IMMUNOLOGY, vol. 14, no. 9, 22 August 2014 (2014-08-22), pages 585-600, XP055227747, GB ISSN: 1474-1733, DOI: 10.1038/nri3707

PATEL DHAVALKUMAR D ET AL: "Effect of IL-17A blockade with secukinumab in autoimmune diseases", ANNALS OF THE RHEUMATIC DISEASES, B M J GROUP, GB, vol. 72, no. Suppl. 2, 1 April 2013 (2013-04-01), pages ii116-ii123, XP009174221, ISSN: 1468-2060

MCINNES I ET AL: "Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial", ARTHRITIS & RHEUMATISM; 75TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY/46TH ANNUAL SCIENTIFIC MEETING, WILEY, US; CHICAGO, IL, USA, vol. 63, no. Suppl. S10, 1 January 2011 (2011-01-01), page S306, XP008147787, ISSN: 0004-3591, DOI: 10.1002/ART.33310 [retrieved on 2011-12-09]

Rita Baron-Faust: "The IL-17 Superfamily: What Future for PsA? The IL-17 Superfamily: What Future for PsA?", Rheumatology Network, 18 March 2014 (2014-03-18), pages 1-5, XP055227427, Retrieved from the Internet: URL:<http://www.rheumatologynetwork.com/psoriatic-arthritis/il-17-superfamily-what-future-psa> [retrieved on 2015-11-10]

JOSHUA E WEITZ ET AL: "Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 14, no. 4, 1 April 2014 (2014-04-01), pages 515-526, XP055226577, ASHLEY, LONDON; GB ISSN: 1471-2598, DOI: 10.1517/14712598.2014.890587

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Sekukinumab for bruk ved hemming av progresjon av strukturell skade ved psoriasisartritt, omfattende subkutan administrering til en pasient av en dose på 150 mg eller 300 mg sekukinumab månedlig, hvor hemming av progresjon av strukturell skade måles gjennom van der Heijdes
5 psoriasisartritt-modifiserte total Sharp score (mTSS).
2. Sekukinumab for bruk ifølge krav 1, hvor endringen fra baseline i mTSS er $\leq 0,5$.
3. Sekukinumab for bruk ifølge krav 1 eller 2, hvor sekukinumab blir administrert i kombinasjon med
10 metotreksat.
4. Sekukinumab for bruk ifølge krav 1 eller 2, hvor sekukinumab blir administrert i kombinasjon med et ikke-steroid antiinflammatorisk medikament (NSAID).
- 15 5. Sekukinumab for bruk ifølge krav 4, hvor NSAID'et er valgt fra gruppen bestående av et propionsyrederivat, eddiksyrederivat, enolsyrederivat, fenaminsyrederivat, Cox-hemmer, lumirakoksib, ibuprofen, fenoprofen, ketoprofen, flurbiprofen, oksaprozin, indometacin, sulindak, etodolak, ketorolak, nabumeton, aspirin, naproksen, valdekoksib, etorikoksib, rofekoksib, acetaminofen, celekoksib, diklofenak, tramadol, piroksikam, meloksikam, tenoksikam, droksikam,
20 lornoksikam, isoksikam, mefanaminsyre, meklofenaminsyre, flufenaminsyre, tolfenam, parekoksib, og firokoksib.